Every 10-Q that Solventum Corporation (SOLV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SOLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOLV filings page.
Solventum Corporation reported mixed results for the quarter ended June 30, 2026. Total net sales were $2,209 million, up from $2,161 million a year earlier, with organic sales growth of 9.5% driven by MedSurg and Dental Solutions and aided by about $125 million of advanced customer orders ahead of a July 2026 ERP deployment, which is expected to pressure third-quarter sales.
Quarterly net income was $92 million and diluted earnings per share were $0.53, little changed from the prior year, while operating income declined to $181 million as higher selling, general and administrative costs offset margin gains from lower cost of product. Results included a $100 million pre-tax benefit from IEEPA tariff refunds recorded in cost of product and $204 million of legal charges, mainly related to product litigation, which increased accrued litigation costs to $235 million.
For the first six months of 2026, net sales were $4,216 million versus $4,231 million and net income fell to $105 million from $227 million, reflecting the absence of a prior-year tax benefit, restructuring and legal costs. Operating cash flow was $38 million, while the company repurchased $355 million of stock and ended June with $403 million in cash and $5,079 million of total debt. Management is executing its four-year “Transform for the Future” program, targeting about $500 million in annual cost savings for roughly $500 million in cumulative pretax costs, and has announced plans to pursue a separation of the Health Information Systems business.
Solventum reported weaker Q1 2026 results, with profit sharply lower despite modest segment growth. Net sales slipped 3% to $2,007 million, while net income fell to $13 million from $137 million, and diluted EPS dropped to $0.07 from $0.78.
MedSurg sales rose 6.6% to $1,234 million, Dental Solutions grew 7.9% to $354 million, and Health Information Systems increased 4.1% to $342 million, but MedSurg margins compressed as tariffs, inflation and separation-related costs outpaced savings. Company‑wide operating margin declined to 4.0% from 7.3%.
Cash flow from operations turned negative at $(189) million versus $29 million a year earlier, reflecting higher incentive and transition payments. Cash and equivalents decreased to $561 million, while total debt stood at $5,080 million. Solventum booked $37 million of new "Transform for the Future" restructuring charges and repurchased 922,636 shares for $67 million under a $1 billion buyback authorization.
Solventum Corporation (SOLV) reported Q3 2025 results highlighted by a completed divestiture and significant de-leveraging. The company sold its Purification and Filtration business to Thermo Fisher for approximately $4 billion cash, recording a pre-tax gain of approximately $1.5 billion (net of $86 million in transaction fees). Q3 diluted EPS was $7.22 on total net sales of $2,096 million.
Long-term debt declined to $5,137 million from $7,810 million at year-end, aided by cash tender offers retiring $1.9 billion of senior notes, which produced an $82 million loss on extinguishment (including instruments activity). Cash and equivalents rose to $1,642 million. Operating cash flow for the nine months was $274 million, reflecting the non-cash nature of the $1,518 million gain and working capital movements. The company recognized an unfavorable contract liability of $113 million tied to transition services and recorded a $64 million liability related to a potential payment of up to $75 million associated with the excluded Water Business.
Q3 gross profit was $1,135 million; SG&A was $780 million and R&D was $183 million. Shares outstanding were 173,439,525 as of September 30, 2025.